_MG_8505-crop-(1).png

Shane Cooke

Chair

  • R
  • N

Shane Cooke

Chair

Shane Cooke (57) was President of Alkermes plc, from September 2011 until his retirement in March 2018. Prior to this, Shane spent 10 years as Chief Financial Officer of Elan Corporation plc from 2001 and from 2007 he also was Head of Elan Drug Technologies. Prior to Elan he held the role of Chief Executive Officer of Pembroke Capital Ltd, an aviation leasing company of which he was a founder.


External Appointments: Shane serves as a non-executive director on the board of Alkermes plc, Prothena Corporation plc and Endo International plc, all publicly-quoted companies.

Shane Cooke sits on the following committees:

Brendan-McAtamney.jpg

Brendan McAtamney

Chief Executive Officer

Brendan McAtamney

Chief Executive Officer

Brendan McAtamney (57) was appointed Group Chief Executive Officer on 2 February 2016, having previously served as the Group’s Chief Operating Officer since 1 September 2013. Before joining UDG Healthcare, Brendan held various senior management positions with Abbott, latterly as Vice President Commercial and Corporate Officer within the Established Pharmaceuticals division.

External Appointments:  Brendan is a non-executive director of Scapa Group plc.

Nigel-Clerkin-May2018.jpg

Nigel Clerkin

Chief Financial Officer

Nigel Clerkin

Chief Financial Officer

Nigel Clerkin (46) joined UDG Healthcare plc as Chief Financial Officer on 1 May 2018. Prior to this, Nigel held the position of CFO with ConvaTec Group plc where he worked for three years. Before this, he worked with Elan Corporation plc both in the U.S. and Europe, holding the position of Executive Vice President and CFO. Nigel started his career at KPMG and is a fellow of the Institute of Chartered Accountants of Ireland.

Linda-Wilding.jpg

Linda Wilding

Non-Executive Director

  • A
  • R
  • N

Linda Wilding

Non-Executive Director

Linda Wilding’s (60) career includes 12 years at Mercury Asset Management where she held the position of Managing Director in the Private Equity division. Prior to this, Linda qualified as a chartered accountant while working with Ernst & Young.

External Appointments: Linda is a non-executive director of BMO Commercial Property Trust, Foreign & Colonial Commercial Property and the Wesleyan Assurance Society.

Linda Wilding sits on the following committees:

Myles-Lee-April-2017teal.jpg (1)

Myles Lee

Senior Independent Director

  • A
  • N

Myles Lee

Senior Independent Director

Myles (66) was Group Chief Executive of CRH plc, a FTSE 100 and Fortune 500 company, prior to retiring in December 2013. With more than 30 years’ experience at senior financial and managerial level, Myles has extensive global experience in management, M&A and finance. He is a qualified civil engineer and a Fellow of the Institute of Chartered Accountants in Ireland.

External Appointments: Myles is a non-executive director of both Ingersoll-Rand Inc. and Babcock International Group plc.

Myles Lee sits on the following committees:

Lisa-Ricci.jpg

Lisa Ricciardi

Non-Executive Director

  • R
  • R
  • A

Lisa Ricciardi

Non-Executive Director

Lisa Ricciardi (59) has been CEO & Chief Business Officer with sell-side experience in VC-backed life science companies (biotech, genomics, medical devices) and buy-side experience as Global Licensing SVP of Pfizer and SVP of U.S. International and business development at Medco Health Solutions. She has led significant and transformational deals at both Pfizer and Medco. From 1 October 2019, Lisa was appointed as a Designated NED for the purposes of the New Code.

External Appointments: Lisa advises various biotechs across the industry.

Lisa Ricciardi sits on the following committees:

Erik-Van-Snippenberg.jpg

Erik Van Snippenberg

Non-Executive Director

  • A
  • R

Erik Van Snippenberg

Non-Executive Director

Erik van Snippenberg (55) spent almost 30 years with GlaxoSmithKline (‘GSK’). More recently, Erik held the position of Senior Vice President and Area Head for Europe and Canada and was a member of GSK’s Global Pharmaceutical Management Team. Prior to this, Erik held a number of senior executive roles such as Senior Vice-President and Director of U.K. and Ireland. Erik was also appointed Designated NED from 1 October 2019 for the purpose of the New Code.

External Appointments: Erik is currently a non-executive director of Eurovite Group.

Erik Van Snippenberg sits on the following committees:

peter-chambre.jpg

Peter Chambré

NON-EXECUTIVE DIRECTOR

  • R

Peter Chambré

NON-EXECUTIVE DIRECTOR

Peter (64) was Chief Executive Officer of Cambridge Antibody Group plc until 2006 and, before that, held the roles of Chief Operating Officer of Celera Genomics Group and Chief Executive Officer of Bespak plc (now Consort Medical plc). More recently, Peter was a non-executive director of Spectris plc until December 2016, and of Touchstone Innovations plc until January 2017.


External Appointments: Peter is Chairman of Immatics Biotechnologies GmbH and a Trustee of Cancer Research U.K.


 

Peter Chambré sits on the following committees:

Liz Shanahan.jpg (1)

Liz Shanahan

Non-executive Director

Liz Shanahan

Non-executive Director

Liz is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., who had in 2007 acquired the communications business, Santé Communications, which she had founded in 1995.


Liz has a degree in Computer Programming & Maths from University College Cork, and she is an alumnus of the University of Virginia, Darden School of Business.


External Appointments: Liz is currently a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London. She is also a member of the organisation’s Innovations Advisory Board.

Anne-Whitaker-Oct2020.jpg

Anne Whitaker

Non-executive Director

Anne Whitaker

Non-executive Director

Anne has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech, and speciality pharma companies. Since October 2018, she has served as the Chief Executive Officer of Aerami Therapeutics (formerly Dance Biopharm Holdings, Inc.), a clinical stage pharmaceutical and medical device company. She has also served as Chief Executive Officer at KNOW Bio, LLC and Novoclem Therapeutics, Inc., a wholly owned subsidiary of KNOW Bio from February 2017 until April 2018. Previously, Anne was Executive Vice President and Company Group Chairman at Bausch Health, where she was responsible for overseeing its Global Branded Pharmaceutical Business. Prior to that, Anne served as President and Chief Executive Officer of Synta Pharmaceuticals. She also served as President, North America Pharmaceuticals at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations for the region and held several commercial leadership roles at GlaxoSmithKline. Until recently, Anne was a Non-Executive Director for the London listed plc, Vectura Group plc.


External Appointments: Anne is also an Independent Director of Cree, Inc., a NASDAQ traded company, and NYSE-listed Mallinckrodt plc. She is also a Trustee for the University of North Alabama.